Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. ViroPharma,'s Revenue for the
three
months ended in Sep. 2013 was €84.6 Mil. ViroPharma,'s Total Assets for the quarter that ended in Sep. 2013 was €846.8 Mil. Therefore, ViroPharma,'s Asset Turnover for the quarter that ended in Sep. 2013 was 0.10.
Asset Turnover is linked to ROE % through Du Pont Formula. ViroPharma,'s annualizedROE % for the quarter that ended in Sep. 2013 was 2.31%. It is also linked to ROA % through Du Pont Formula. ViroPharma,'s annualizedROA % for the quarter that ended in Sep. 2013 was 1.48%.
ViroPharma, Asset Turnover Historical Data
The historical data trend for ViroPharma,'s Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ViroPharma,'s Asset Turnover
For the Biotechnology subindustry, ViroPharma,'s Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroPharma,'s Asset Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ViroPharma,'s Asset Turnover distribution charts can be found below:
* The bar in red indicates where ViroPharma,'s Asset Turnover falls into.
ViroPharma, Asset Turnover Calculation
Asset Turnover measures how quickly a company turns over its asset through sales.
ViroPharma,'s Asset Turnover for the fiscal year that ended in Dec. 2012 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
ViroPharma, (FRA:VPH) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
ViroPharma,'s annulizedROE % for the quarter that ended in Sep. 2013 is
Note:
The Net Income data used here is four times the quarterly (Sep. 2013) net income data. The Revenue data used here is four times the quarterly (Sep. 2013) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
ViroPharma,'s annulizedROA % for the quarter that ended in Sep. 2013 is
Note:
The Net Income data used here is four times the quarterly (Sep. 2013) net income data. The Revenue data used here is four times the quarterly (Sep. 2013) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
ViroPharma, Asset Turnover Related Terms
Thank you for viewing the detailed overview of ViroPharma,'s Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
ViroPharma, Inc. was incorporated in Delaware in September 1994 and commenced operations in December 1994. It is a biotechnology company which develops and commercializes products that address serious diseases, used by physician specialists or in hospital settings. The Company's main development programs include C1 esterase inhibitor and a non-toxigenic strain of C. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze was obtained in October 2008, and On 8 January 2010, the company obtained expanded rights to commercialize Cinryze and future C1-INH derived products in certain European countries and other territories throughout the world as well as rights to develop future C1-INH derived products for additional indications. The Company also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection, or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The Company's product development portfolio is consists of programs such as C1 esterase inhibitor [human], maribavir for cytomegalovirus infection, VP20621: prevention of recurrent CDAD and VP20629: treatment of Friedreich's Ataxia. The Company is working on developing further therapeutic uses; potential additional indications in other C1 mediated diseases, and alternative modes of administration for C1 esterase inhibitor. It is also developing VP20621 for the treatment and prevention of CDAD. On September 30, 2011, it entered into a license agreement for the worldwide rights of Intellect Neurosciences, Inc. to its clinical stage drug candidate, VP-20629, which is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease. Its main competitors include both public and private entities, including well-known, large pharmaceutical companies, chemical companies, biotechnology companies and research institutions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:VPH has been successfully added to your 